Skip to main content

Year: 2025

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held September 24 – 26, 2025 in Barcelona, Spain. Abstracts are now available online and can be accessed on the ECTRIMS meeting website or at the following link: ECTRIMS 2025 PROGRAMME. Details of the upcoming presentations are outlined below. TG PRESENTATIONS: Oral Presentation: Long-term Efficacy and Safety of Ublituximab in Relapsing Multiple Sclerosis: Results from Six Years of ULTIMATE I and II Open-label ExtensionPresentation Date/Time: Wednesday, September 24th at...

Continue reading

FTI Consulting Bolsters Threat Intelligence Capabilities with Appointment of Keith Wojcieszek

WASHINGTON, Sept. 10, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of threat intelligence expert Keith Wojcieszek as a Senior Managing Director in the Cybersecurity practice within the firm’s Forensic and Litigation Consulting segment. Mr. Wojcieszek, who is based in Washington, D.C., has more than 15 years of experience in cybersecurity intelligence, cyber crime, data loss, incident response investigations and cybersecurity compliance. His experience also includes serving as an expert witness in court cases involving security breach litigation. In his role at FTI Consulting, Mr. Wojcieszek will help clients leverage threat intelligence capabilities to anticipate, identify and respond to cyber threats, empowering informed, threat-based decisions and enhancing cyber resilience. “As the...

Continue reading

Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association

Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or older Abstract is now available on ANA2025 websiteLAKE FOREST, Ill., Sept. 10, 2025 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs, today announced that the company will present new data for SYMPAZAN (clobazam) Oral Film in a poster presentation at the 150th Annual Meeting of the American Neurological Association (ANA2025), September 13-16, 2025, Baltimore Marriott Waterfront, Baltimore. The poster presentation will expand on data from...

Continue reading

OptimizeRx to Participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference

WALTHAM, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference taking place Thursday, September 11, 2025, in New York, NY. To request a meeting or for more details about the Conference, please reach out to your institutional contact. About OptimizeRx OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to...

Continue reading

Abaxx Exchange and Zhonggong Natural Gas Explore LNG Procurement Partnership

TORONTO, Sept. 10, 2025 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd. (“Abaxx Singapore”), the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, today announced that Abaxx Exchange and Zhonggong Petroleum & Natural Gas Co., Ltd. (“Zhonggong”), a fast-growing energy company with provincial-level priority projects in North and Southwest China, developed in coordination with the National Energy Administration, intend to explore a partnership in liquefied natural gas (“LNG”) procurement and related trading services. The cooperation is expected to connect Zhonggong’s growing...

Continue reading

Sparton Resources Inc. VRB China Announcement

200 Mega Watt Hour Project Successful Bid TORONTO, Sept. 10, 2025 (GLOBE NEWSWIRE) — Sparton Resources (TSX-SRI-V), (“the Company”), is pleased to report news from VRB China. It was announced September 5, 2025, that Beijing Puneng Century Technology Co. Ltd. (“BJP”) has successfully won the bid to construct a 50 Megawatt, 200-Megawatt Hour all-vanadium liquid flow battery energy storage power station in Longzhouping Town, Changyang, Hubei Province PRC. This announcement marks a significant milestone in the progress of the VRB China Joint Venture, which is 51% owned by Shanxi Red Sun Co., Ltd. (“Red Sun”) and 49% owned by VRB Energy Inc. (“VRB Energy”) through its 100% ownership of BJP. Sparton’s interest in the flow battery industry is a 9.975% interest in VRB Energy Inc. held through Sparton’s 90% interest in VanSpar Mining Inc....

Continue reading

Brixton Metals Drills 29m of 1.75 g/t Gold Including 7.5m of 3 g/t Gold at its Trapper Gold Target, Thorn Project

VANCOUVER, British Columbia, Sept. 10, 2025 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) (the “Company” or “Brixton”) is pleased to report initial drill results from its near-surface program at the Trapper Gold Target. These results represent the first 9 of 27 holes completed to date at Trapper for a combined total of 5392m. Also, a total of 6 holes for a combined 2960.5m have been drilled at Catalyst and Tempest (assays pending). The Company is advancing its exploration efforts with two drill rigs operating concurrently, one at the Trapper Gold Target and the other at the Catalyst and Tempest Cu-Au Porphyry Targets. Highlights from TrapperShallow drilling was successful in extending gold-silver mineralization southeast of the main mineralized zone at TrapperHole THN25-335 returned 29m of 1.75 g/t...

Continue reading

Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market

First of its kind report offers insight from over 110 biopharma executives into the benefits of royalties, current market dynamics and outlook for royalty market expansion Royalties have become integral to biopharma’s diversified capital landscape driven by attractive cost of capital, flexibility and positive investor perceptionNEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced the release of a biopharma royalty market study conducted by Deloitte. The report, titled “Role of Royalties in Funding Biopharma Innovation,” is the first of its kind and offers a comprehensive analysis of the current dynamics, growth drivers and outlook for biopharma royalties. The full report is available for download at Deloitte’s website and Royalty Pharma’s website. “Our report takes a deep...

Continue reading

Bombardier Contributed $7.4 Billion to Canadian GDP in 2024, PwC Study Shows

Bombardier had a total contribution (direct, indirect and induced) of $7.4 billion to Canada’s GDP in 2024 and supported close to 50,000 jobs across the country  In 2024, the company contributed over $1.2 billion in revenues to provincial and federal governments, including taxes on income, products and production  In Quebec, Bombardier directly supported more than 31% of the aerospace sector’s employment, making it one of the largest employers in the province’s manufacturing industryAll amounts in this press release are in Canadian dollars, unless otherwise indicated.TORONTO, Sept. 10, 2025 (GLOBE NEWSWIRE) — A study by PwC Canada provides an update on the substantial economic and social contributions of Bombardier’s manufacturing operations in Canada. Indicators such as the GDP, exports and supported jobs presented...

Continue reading

AOI Advances Its Software Suite with New AI Intelligence Modules for Smarter Networks

SUGAR LAND, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) — Applied Optoelectronics Inc. (NASDAQ: AAOI), a leading provider of advanced optical and HFC networking products that power the internet, today announced the addition of four new software modules to its QuantumLink™ HFC Remote Management solution, offering customers actionable intelligence to optimize network performance, reduce operational costs, and improve the broadband experience. The new suite of software modules are add-ons to AOI’s existing QuantumLink Central providing telemetry, adding unified visibility, predictive diagnostics, and automated controls to its remote amplifier management platform. Field technicians can access the simple-to-use web app to connect to AOI’s QuantumLink Transponder inside the amplifier, which uses the LoRaWAN standard protocol to communicate...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.